2021
Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Fariñas S, Exposito F, Serrano D, Redin E, Valencia K, Jantus-Lewintre E, Diaz-Lagares A, Montuenga L, Sandoval J, Calvo A. Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers 2021, 13: 3016. PMID: 34208598, PMCID: PMC8233712, DOI: 10.3390/cancers13123016.Peer-Reviewed Original ResearchLiquid biopsyEpigenetic biomarkersSpecific epigenetic alterationsDNA methylation changesTumor microenvironmentDNA promoter methylationCommon clinical practiceHigh-incidence malignancyActionable genetic alterationsCancer drug responseSingle geneEpigenetic eventsDNA methylationGene setsMethylation changesTypes of cancerEpigenetic alterationsPrimary tumorClinical trialsClinical valueCerebrospinal fluidHigh incidenceTissue biopsiesClinical practiceEarly alterations
2017
miR-146a targets c-met and abolishes colorectal cancer liver metastasis
Bleau AM, Redrado M, Nistal-Villan E, Villalba M, Exposito F, Redin E, de Aberasturi AL, Larzabal L, Freire J, Gomez-Roman J, Calvo A. miR-146a targets c-met and abolishes colorectal cancer liver metastasis. Cancer Letters 2017, 414: 257-267. PMID: 29133238, DOI: 10.1016/j.canlet.2017.11.008.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesMiR-146aColorectal cancerPrimary tumorColorectal cancer liver metastasesLiver metastatic variantsMC38 adenocarcinoma cellsCancer liver metastasesCRC patientsMajor complicationsTreatment optionsDisease progressionMouse modelMetastasisMetastatic clonesSerial transplantationAdenocarcinoma cellsGene expression arraysHigh expressionMetastatic variantsDeadliest typesNew targetsMicroRNA profilingExpression levels